

Confidential

Date and Time: Thursday 2nd & 3rd February 2012, 1000 - 1600

Minutes: Confirmed

Guideline Development Group Meeting

Place: *National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ.*

Present: Alan Lobo, Consultant Physician & Gastroenterologist (Chair)
 Adam Harris, Consultant Physician & Gastroenterologist
 Eshan Senanayake, General Practitioner
 Assad Butt, Consultant Physician & Gastroenterologist
 David Bartolo, Consultant Colorectal Surgeon
 Kerry Robinson, IBD Clinical Nurse Specialist
 Valda Forbes, Gastroenterology & Hepatology Clinical Nurse Specialist
 Sarah Cripps, Gastroenterology Pharmacist
 Nigel Westwood, Patient Member
 Kate Kelley, Associate Director, NCGC
 Nancy Pursey, Senior Project Manager, NCGC
 Rachel Wheeler, Research Fellow, NCGC
 Lola Adedokun, Health Economist, NCGC
 Paul Miller, Senior Information Scientist, NCGC (present for item 7)

Apologies: Jeremy Nightingale, Consultant General Physician & Gastroenterologist
 Parastoo Karimi, Patient Member
 Bernard Higgins, Clinical Director, NCGC
 Paul Miller, Senior Information Scientist, NCGC

In attendance:

NICE Staff:		
NICE attendee 1	Clifford Middleton	Present from item 3 onwards
NICE attendee 2		

Observers:

--	--	--

Notes

- Welcome and declarations of interest**
 The chair welcomed the guideline development group (GDG) to GDG meeting 4 and 5 (two day meeting). The Chair asked all GDG members to declare any relevant conflicts of interest. Val Forbes declared a personal pecuniary interest, which was deemed to be reimbursement of reasonable travel expenses and therefore not a conflict of interest. Prior to the meeting, Adam Harris declared a personal pecuniary interest in relation to reimbursement of travel expenses and these were also deemed to be reasonable and

Notes

therefore not a conflict of interest. Assad Butt declared that he has applied to MSD for a non-educational grant to help fund a nurse specialist, and it was deemed that this will not affect his participation.

Jeremy Nightingale has a relevant conflict of interest but was not present.

Nigel Westwood has a conflict of interest and did not participate in the formulation of recommendations.

2. **Evidence review: oral steroids for induction of remission**
The GDG reviewed the evidence for oral steroids.
3. **Update on NICE quality standards**
Clifford Middleton explained that as part of an internal restructure at NICE, quality standards will now be developed in house by NICE. Parallel development of clinical guidelines and quality standards has been stopped. Therefore the GDG will develop the clinical guideline for ulcerative colitis as planned but not the quality standards.
4. **Evidenced review: oral and rectal steroids for induction of remission**
The GDG reviewed the evidence for oral and rectal steroids for induction of remission
5. **Evidence review: rectal aminosalicylates (ASAs) vs. oral ASAs**
The GDG reviewed the evidence for rectal ASAs vs. oral ASAs for induction of remission.
6. **Evidence review: tacrolimus for induction of remission**
The GDG reviewed the evidence for tacrolimus for induction of remission.
7. **Protocols for upcoming review questions**
The GDG discussed protocols for upcoming review questions.
8. **Evidence review: immunomodulators for induction of remission**
The proposed work plan and areas for original modelling were discussed.
9. **Evidence review: acute severe colitis**
The GDG reviewed the evidence for induction of remission in acute severe colitis.
10. **GDG3 minutes**
The minutes were agreed to be a true and accurate record of the meeting.
11. **Summary of recommendations**
The GDG reviewed the recommendations made to date for induction of remission.
12. **Original model for induction of remission**
The GDG discussed and agreed treatment sequences for inclusion in the model.

Date, time and venue of the next meeting

Wednesday 14th March 2012, from 1000 until 1600.

Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ